Logo image of AVXL

ANAVEX LIFE SCIENCES CORP (AVXL) Stock Fundamental Analysis

NASDAQ:AVXL - Nasdaq - US0327973006 - Common Stock - Currency: USD

7.78  +0.25 (+3.32%)

After market: 7.7499 -0.03 (-0.39%)

Fundamental Rating

3

AVXL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AVXL as it has an excellent financial health rating, but there are worries on the profitability. AVXL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AVXL has reported negative net income.
In the past year AVXL has reported a negative cash flow from operations.
AVXL had negative earnings in each of the past 5 years.
AVXL had a negative operating cash flow in each of the past 5 years.
AVXL Yearly Net Income VS EBIT VS OCF VS FCFAVXL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -37.48%, AVXL is in line with its industry, outperforming 57.75% of the companies in the same industry.
AVXL has a better Return On Equity (-41.92%) than 68.98% of its industry peers.
Industry RankSector Rank
ROA -37.48%
ROE -41.92%
ROIC N/A
ROA(3y)-31.3%
ROA(5y)-38.71%
ROE(3y)-34.3%
ROE(5y)-44.93%
ROIC(3y)N/A
ROIC(5y)N/A
AVXL Yearly ROA, ROE, ROICAVXL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

AVXL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVXL Yearly Profit, Operating, Gross MarginsAVXL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for AVXL has been increased compared to 1 year ago.
AVXL has more shares outstanding than it did 5 years ago.
There is no outstanding debt for AVXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVXL Yearly Shares OutstandingAVXL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AVXL Yearly Total Debt VS Total AssetsAVXL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 25.06 indicates that AVXL is not in any danger for bankruptcy at the moment.
AVXL has a Altman-Z score of 25.06. This is amongst the best in the industry. AVXL outperforms 96.08% of its industry peers.
There is no outstanding debt for AVXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 25.06
ROIC/WACCN/A
WACCN/A
AVXL Yearly LT Debt VS Equity VS FCFAVXL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 9.45 indicates that AVXL has no problem at all paying its short term obligations.
AVXL has a Current ratio of 9.45. This is in the better half of the industry: AVXL outperforms 78.25% of its industry peers.
AVXL has a Quick Ratio of 9.45. This indicates that AVXL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.45, AVXL is in the better half of the industry, outperforming 78.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.45
Quick Ratio 9.45
AVXL Yearly Current Assets VS Current LiabilitesAVXL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for AVXL have decreased strongly by -10.00% in the last year.
EPS 1Y (TTM)-10%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AVXL will show a very strong growth in Earnings Per Share. The EPS will grow by 94.58% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-24.23%
EPS Next 2Y114.68%
EPS Next 3Y110.2%
EPS Next 5Y94.58%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVXL Yearly Revenue VS EstimatesAVXL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
AVXL Yearly EPS VS EstimatesAVXL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15 20 25

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

AVXL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 5.73, the valuation of AVXL can be described as very cheap.
97.86% of the companies in the same industry are more expensive than AVXL, based on the Price/Forward Earnings ratio.
AVXL is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.94, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 5.73
AVXL Price Earnings VS Forward Price EarningsAVXL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVXL Per share dataAVXL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

AVXL's earnings are expected to grow with 110.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y114.68%
EPS Next 3Y110.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AVXL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANAVEX LIFE SCIENCES CORP

NASDAQ:AVXL (5/21/2025, 8:00:00 PM)

After market: 7.7499 -0.03 (-0.39%)

7.78

+0.25 (+3.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners35.04%
Inst Owner Change6.32%
Ins Owners3.04%
Ins Owner Change7.75%
Market Cap664.18M
Analysts82.22
Price Target36.69 (371.59%)
Short Float %28.45%
Short Ratio23.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.61%
Min EPS beat(2)15.96%
Max EPS beat(2)19.26%
EPS beat(4)3
Avg EPS beat(4)8.39%
Min EPS beat(4)-15.86%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)13.42%
EPS beat(12)9
Avg EPS beat(12)10.46%
EPS beat(16)11
Avg EPS beat(16)9.48%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.67%
EPS NY rev (1m)0.52%
EPS NY rev (3m)1.81%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.73
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.99
P/tB 5.99
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)1.36
Fwd EY17.44%
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0
BVpS1.3
TBVpS1.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.48%
ROE -41.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.3%
ROA(5y)-38.71%
ROE(3y)-34.3%
ROE(5y)-44.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.45
Quick Ratio 9.45
Altman-Z 25.06
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-24.23%
EPS Next 2Y114.68%
EPS Next 3Y110.2%
EPS Next 5Y94.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year369.85%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.24%
OCF growth 3YN/A
OCF growth 5YN/A